论文部分内容阅读
Inex公司的长春新碱（incristin川g质体（商品名OncoTCS）能使对原先化疗无效的晚期非霍奇金淋巴瘤（NHL）病人的肿瘤有明显缩小。一项fi期临床研究的早期结果表明用本品治疗的21例可评估的NHL病人的总有效率为45％。Inex公司开发了一种名为经膜载体系统（transmembranecarrier
Inex’s Vincristine (increased oncoTCS) can significantly reduce tumors in patients with advanced non-Hodgkin’s lymphoma (NHL) that were not responding to previous chemotherapy. The total effective rate of 21 appraisable NHL patients treated with this product was 45%.Inex company developed a transmembrane carrier system (transmembrane carrier).